Executive brief
21 CFR Part 11 compliance refers to meeting the U.S. Food and Drug Administration requirements for electronic records and electronic signatures used in regulated environments. For life sciences companies, this regulation defines how systems, processes, and controls must work so electronic records are trustworthy, reliable, and equivalent to paper records.
The goal of 21 CFR Part 11 compliance is not just technical control. It is operational accountability. Organizations must be able to show who accessed a record, what changed, when it changed, why it changed, and whether the system can prevent unauthorized activity. In practice, that means compliant environments need validated systems, secure access controls, robust audit trails, and traceable eSignature processes.
Are authority checks in place so only approved users can sign, edit, or review records?
Are electronic signatures permanently linked to the record and captured with the signer’s name, date, time, and meaning?
For regulated companies, 21 CFR Part 11 compliance is closely tied to product quality, patient safety, inspection readiness, and business continuity. Electronic systems are now central to quality, manufacturing, clinical, and regulatory operations. If those systems are not compliant, the risk is not limited to documentation gaps. It can affect data integrity, submission readiness, audit outcomes, and confidence in the business process itself.
This is why Trust & Compliance has to be built into the operating model, not bolted on after deployment.
A strong 21 CFR Part 11 compliance program typically includes several foundational controls.